FDA Gets Dozens Of Complaints After Ranbaxy Recall
In a potential boost for a proposed class action, patients using Ranbaxy Laboratories Ltd.'s generic version of Lipitor have submitted to regulators dozens of complaints, many involving intestinal hemorrhages and abdominal...To view the full article, register now.
Already a subscriber? Click here to view full article